Esperion's cholesterol drugs drive 77% stock surge after FDA approvals

Esperion Therapeutics has witnessed a notable surge in its stock market value, fueled by growing confidence in its cholesterol-lowering drugs. The company's treatments, Nexletol and Nexlizet, recently gained broader approval and recognition in key medical guidelines. This shift has sparked optimism among investors and cardiologists alike.

In March 2024, the FDA expanded the approval for Nexletol and Nexlizet, enabling their use in both primary and secondary prevention of cardiovascular events. This decision widened the potential patient base, increasing the drugs' market reach.

The active ingredient, bempedoic acid, was later included in guidelines from the European Society of Cardiology and European Atherosclerosis Society. Experts anticipate this endorsement to shape future treatment recommendations in the U.S., further bolstering adoption.

A survey by Piper Sandler revealed strong support among cardiologists. Of the 26 specialists questioned, 35% predicted a substantially larger role for the drugs, while 46% anticipated a moderate increase in prescriptions. Analyst David Amsellem forecasted peak U.S. revenues for Nexletol and Nexlizet to surpass $650 million.

Esperion's market position remains secure, with exclusivity agreements safeguarding Nexletol and Nexlizet from generic competition until 2040. Investor confidence grew after Piper Sandler initiated coverage with an 'Overweight' rating and a $9 price target. The company's stock soared by around 16% following the announcement.

By February 2026, Esperion's share price had climbed to $3.55, indicating a 77% increase since its fair value classification by InvestingPro in April 2024. However, the upward trend was not consistent, with several fluctuations along the way.

The expanded approval and guideline inclusion have positioned Nexletol and Nexlizet for wider use. With market exclusivity secured until 2040, Esperion Therapeutics stands to gain from long-term revenue growth. The stock's performance reflects rising expectations, though its trajectory has exhibited periodic volatility on the stock market today.